CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
Capital Com Australia Pty Ltd Australia (受监管于 ASIC) Capital Com UK Limited 受监管于 Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (受监管于 CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (受监管于 NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (受监管于 FSA) Capital Com Online Investments Ltd (受监管于 SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
您也可以联系我们： 致电 +44 2030978888 support@capital.com

交易 Inozyme Pharma, Inc. - INZY CFD

-
0%
  • 概括
  • 历史数据
  • 活动
  • 收入报表
  • 资产负债表
  • 现金流
  • 所有权
交易条件
价差 -
多头隔夜费

Long position overnight fee

Margin. Your investment $1,000.00
隔夜费用 -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
-0.024068%
空头隔夜费

Short position overnight fee

Margin. Your investment $1,000.00
隔夜费用 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
0.001846%
隔夜费时间 21:00 (UTC)
最小交易量 1
货币 USD
保证金 20%
上市交易所 United States of America
交易费 0%

*Information provided by Capital.com

关键数据
前收盘价* N/A
开盘价* N/A
1 年变化* N/A
日范围* N/A
52 周范围 0.99-6.25
平均交易量（10 天） 744.45K
平均交易量（3 个月) 28.94M
市值 110.28M
市盈率 -100.00K
流通股 40.39M
收入 N/A
EPS -2.26
股息（收益率 %） N/A
贝塔 -100.00K
下一个财报发布日期 Mar 21, 2023

所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date 平倉 Change Change (%) 開倉 High Low

Inozyme Pharma, Inc. Events

時間（協調世界時） (UTC) 國家 事件
No events scheduled
查看所有活動
  • 年度
  • 每季度
2021 2020 2019 2018
总收入 0 0 0 0
总营业费用 56.646 57.041 20.806 11.593
销售/一般/行政费用，总计 18.926 10.548 4.586 3.494
研究与开发 37.72 46.493 16.22 8.099
营业收入 -56.646 -57.041 -20.806 -11.593
利息收入（费用），非经营净值 0.211 0.37 1.106 0.284
其他，净值 -0.189 0.247 -0.024 4.345
税前净收入 -56.624 -56.424 -19.724 -6.964
税后净收入 -56.624 -56.424 -19.724 -6.964
未计算非常项目前的净收益 -56.624 -56.424 -19.724 -6.964
净收入 -56.624 -56.424 -19.724 -6.964
普通股股东可获收益 (不含非经常性项目) -56.624 -56.424 -19.724 -6.964
普通股股东可获收益 (含非經常性項目) -56.624 -56.424 -19.724 -6.964
摊薄净收入 -56.624 -56.424 -19.724 -6.964
摊薄后加权平均股 23.5583 11.0365 20.3148 20.3148
扣除特别项目的每股摊薄盈利 -2.40357 -5.11249 -0.97092 -0.3428
Dividends per Share - Common Stock Primary Issue 0 0
每股正常摊薄盈利 -2.40357 -5.11249 -0.97092 -0.3428
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
总收入 0 0 0 0 0
总营业费用 16.839 18.757 14.262 12.655 10.972
销售/一般/行政费用，总计 5.025 5.206 4.916 4.435 4.369
研究与开发 11.814 13.551 9.346 8.22 6.603
营业收入 -16.839 -18.757 -14.262 -12.655 -10.972
利息收入（费用），非经营净值 0.06 0.043 0.047 0.058 0.063
其他，净值 -0.105 -0.04 -0.065 0.057 -0.141
税前净收入 -16.884 -18.754 -14.28 -12.54 -11.05
税后净收入 -16.884 -18.754 -14.28 -12.54 -11.05
未计算非常项目前的净收益 -16.884 -18.754 -14.28 -12.54 -11.05
净收入 -16.884 -18.754 -14.28 -12.54 -11.05
普通股股东可获收益 (不含非经常性项目) -16.884 -18.754 -14.28 -12.54 -11.05
普通股股东可获收益 (含非經常性項目) -16.884 -18.754 -14.28 -12.54 -11.05
摊薄净收入 -16.884 -18.754 -14.28 -12.54 -11.05
摊薄后加权平均股 23.6863 23.6673 23.6435 23.4906 23.4295
扣除特别项目的每股摊薄盈利 -0.71282 -0.7924 -0.60397 -0.53383 -0.47163
Dividends per Share - Common Stock Primary Issue 0 0 0 0
每股正常摊薄盈利 -0.71282 -0.7924 -0.60397 -0.53383 -0.47163
  • 年度
  • 每季度
2021 2020 2019 2018
流动资产总额 115.342 150.979 47.46 43.267
现金和短期投资 111.801 147.697 47.132 43.163
现金等价物 23.316 28.04 31.605 35.966
短期投资 88.485 119.657 15.527 7.197
应收账款总额，净额 0.062 0.155 0.104 0.031
Prepaid Expenses 3.479 3.127 0.224 0.073
Total Assets 123.541 169.363 47.944 43.543
Property/Plant/Equipment, Total - Net 4.436 2.648 0.298 0.242
Property/Plant/Equipment, Total - Gross 5.437 2.975 0.408 0.269
Accumulated Depreciation, Total -1.001 -0.327 -0.11 -0.027
Other Long Term Assets, Total 3.763 3.537 0.186 0.034
Total Current Liabilities 11.633 9.973 3.236 2.389
Accounts Payable 2.394 3.069 0.901 0.984
Accrued Expenses 9.239 6.625 2.335 1.405
Notes Payable/Short Term Debt 0 0 0 0
Total Liabilities 14.273 11.26 3.236 2.389
Total Long Term Debt 0 0 0 0
Total Equity 109.268 158.103 44.708 41.154
Preferred Stock - Non Redeemable, Net 77.927 55.029
Common Stock 0.002 0.002 0.001 0.001
Additional Paid-In Capital 256.948 249.175 1.427 1.054
Retained Earnings (Accumulated Deficit) -147.7 -91.076 -34.652 -14.928
Other Equity, Total 0.018 0.002 0.005 -0.002
Total Liabilities & Shareholders’ Equity 123.541 169.363 47.944 43.543
Total Common Shares Outstanding 23.6726 23.385 20.3148 20.3148
Total Preferred Shares Outstanding 72.4164
Long Term Investments 0 12.199
Other Current Liabilities, Total 0 0.279
Other Liabilities, Total 2.64 1.287
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
流动资产总额 100.583 115.342 130.579 140.962 148.041
现金和短期投资 97.773 111.801 125.283 137.464 145.086
现金等价物 31.943 23.316 27.229 26.239 16.486
短期投资 65.83 88.485 98.054 111.225 128.6
应收账款总额，净额 0.048 0.062 0.073 0.095 0.122
Prepaid Expenses 2.762 3.479 5.223 3.403 2.833
Total Assets 108.931 123.541 137.746 148.259 158.915
Property/Plant/Equipment, Total - Net 4.184 4.436 4.743 4.859 5.029
Property/Plant/Equipment, Total - Gross 5.363 5.437 5.562 5.511 5.514
Accumulated Depreciation, Total -1.179 -1.001 -0.819 -0.652 -0.485
Long Term Investments 0 0 0 2.548
Other Long Term Assets, Total 4.164 3.763 2.424 2.438 3.297
Total Current Liabilities 12.26 11.633 8.943 6.972 6.832
Accounts Payable 2.2 2.394 0.626 0.796 1.709
Accrued Expenses 10.06 9.239 8.317 6.176 5.123
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 14.702 14.273 11.772 9.985 10.026
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 2.442 2.64 2.829 3.013 3.194
Total Equity 94.229 109.268 125.974 138.274 148.889
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 258.94 256.948 254.915 252.92 251.001
Retained Earnings (Accumulated Deficit) -164.584 -147.7 -128.946 -114.666 -102.126
Other Equity, Total -0.129 0.018 0.003 0.018 0.012
Total Liabilities & Shareholders’ Equity 108.931 123.541 137.746 148.259 158.915
Total Common Shares Outstanding 23.8184 23.6726 23.6647 23.5706 23.4737
Other Current Liabilities, Total 0 0 0
Preferred Stock - Non Redeemable, Net 0 0
  • 年度
  • 每季度
2021 2020 2019 2018
净收入/起跑线 -56.624 -56.424 -19.724 -6.964
经营活动产生的现金 -48.153 -35.974 -18.81 -9.437
经营活动产生的现金 0.674 0.217 0.083 0.026
非现金物品 7.712 20.344 0.23 -3.93
营运资金的变化 0.085 -0.111 0.601 1.431
投资活动产生的现金 42.796 -117.179 -8.391 9.006
资本支出 -0.397 -0.568 -0.139 -0.259
其他投资现金流量项目，总计 43.193 -116.611 -8.252 9.265
融资活动产生的现金 0.609 149.812 22.97 31.945
股票的发行（报废），净额 0.609 149.812 22.97 31.945
现金净变化 -4.724 -3.341 -4.231 31.514
外汇效应 0.024
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -16.884 -56.624 -37.87 -23.59 -11.05
Cash From Operating Activities -14.16 -48.153 -34.709 -22.409 -12.376
Cash From Operating Activities 0.178 0.674 0.492 0.325 0.158
Non-Cash Items 1.779 7.712 5.567 3.689 1.725
Changes in Working Capital 0.767 0.085 -2.898 -2.833 -3.209
Cash From Investing Activities 22.562 42.796 33.309 20.247 0.573
Capital Expenditures -0.017 -0.397 -0.357 -0.278 -0.088
Other Investing Cash Flow Items, Total 22.579 43.193 33.666 20.525 0.661
Cash From Financing Activities 0.24 0.609 0.598 0.361 0.249
Issuance (Retirement) of Stock, Net 0.24 0.609 0.598 0.361 0.249
Net Change in Cash 8.627 -4.724 -0.811 -1.801 -11.554
Foreign Exchange Effects -0.015 0.024 -0.009
投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
Longitude Capital Management Co., LLC Venture Capital 10.3341 4174379 1355000 2022-04-19 LOW
Sofinnova Investments, Inc Venture Capital 9.0491 3655308 0 2022-12-31 MED
Deep Track Capital LP Hedge Fund 8.0457 3250000 0 2022-12-31 MED
Adage Capital Management, L.P. Hedge Fund 7.6747 3100138 503466 2022-12-31 LOW
Rock Springs Capital Management LP Hedge Fund 7.6397 3086027 278409 2022-12-31 LOW
VR Adviser, LLC Venture Capital 6.7088 2709987 0 2022-12-31 MED
Pivotal Bioventure Partners Investment Advisor LLC Investment Advisor 6.5879 2661154 0 2022-12-31 LOW
New Enterprise Associates (NEA) Venture Capital 6.0347 2437689 -6690 2022-12-31 LOW
Cowen Investment Management LLC Investment Advisor/Hedge Fund 5.4584 2204876 208599 2022-12-31 MED
Sphera Funds Management Ltd. Hedge Fund 5.1895 2096258 471200 2023-03-03 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.3263 1343622 559 2022-12-31 LOW
Affinity Asset Advisors LLC Hedge Fund 1.2378 500000 500000 2022-12-31 HIGH
Millennium Management LLC Hedge Fund 0.7376 297936 127752 2022-12-31 HIGH
Laurion Capital Management LP Hedge Fund 0.6729 271800 0 2022-12-31 HIGH
Bolte (Axel) Individual Investor 0.6483 261890 3315 2022-09-30 LOW
Renaissance Technologies LLC Hedge Fund 0.6409 258900 103500 2022-12-31 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.6362 256970 -1351 2022-12-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5771 233126 -559 2022-12-31 LOW
BioImpact Capital LLC Investment Advisor/Hedge Fund 0.5706 230500 -430644 2022-12-31 LOW
Overbrook Management Corporation Investment Advisor 0.543 219326 150000 2022-12-31 LOW

为什么选择 Capital.com？让我们的数字来说话。

Capital.com Group

500K+

交易者

92K+

每月活跃客户

$53M+

每月投资额

$30M+

每月提取金额

交易計算器

如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。

貿易佣金
0
  • 1:1
杠杆
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
投資
交易規模（槓桿 x 投資）：
開倉

平倉

做空 做多
過去的表現並不是未來結果的可靠指標
盈利/失利

Inozyme Pharma, Inc. Company profile

关于 Inozyme Pharma Inc.

Inozyme Pharma, Inc.是一家处于临床阶段的罕见疾病生物制药公司。 该公司专注于开发治疗影响血管、软组织和骨骼的异常矿化疾病的疗法。 该公司还专注于开发一种治疗罕见遗传病的疗法，即八核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）和ATP结合盒亚家族C成员6（ABCC6）的缺陷。 公司的主要候选产品INZ-701是一种可溶性、重组或基因工程的融合蛋白，旨在纠正ENPP1和ABCC6缺陷引起的矿化途径的缺陷。

Industry: Biotechnology & Medical Research (NEC)

321 Summer Street
Suite 400
BOSTON
MASSACHUSETTS 02210
US

收入报表

  • Annual
  • Quarterly

人们也观看

Oil - Crude

69.44 Price
+2.310% 1D Chg, %
多头隔夜费 -0.0194%
空头隔夜费 -0.0026%
隔夜费时间 21:00 (UTC)
价差 0.03

Gold

1,941.54 Price
-1.900% 1D Chg, %
多头隔夜费 -0.0177%
空头隔夜费 0.0095%
隔夜费时间 21:00 (UTC)
价差 0.33

BTC/USD

28,106.50 Price
+0.010% 1D Chg, %
多头隔夜费 -0.0616%
空头隔夜费 0.0137%
隔夜费时间 21:00 (UTC)
价差 66.00

US100

12,735.20 Price
+1.320% 1D Chg, %
多头隔夜费 -0.0241%
空头隔夜费 0.0018%
隔夜费时间 21:00 (UTC)
价差 1.8

还在找一位您可以信任的经纪商吗？

加入成为全球500,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易